FDA Approval Of Rylaze Fills Asparaginase Shortage Gap, Offers New Hope For ALL/LBL Patients In June 2021, the U.S. Food and Drug Administration (FDA) approved Rylaze (JZP458, recombinant Owenella asparaginase) for the treatment of patients…
Introduction Aspaveli (pegcetacoplan) is a C3 complement inhibitor used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. It is specifically prescribed for patients who remain anemic after at least three months of treatment…
Japanese pharmaceutical company Fuji Yakuhin Co., Ltd. announced that Urece Tablet (Dotinurad Tablet), a novel uric acid-lowering drug developed by the company, has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is…
About Vonvendi Vonvendi (vonicog alfa) is a recombinant von Willebrand factor (VWF) developed by Baxalta. It helps control bleeding episodes by replacing or supplementing the missing or dysfunctional VWF in patients, thereby improving their quality…
Lachen, Switzerland – Octapharma has announced that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe hemophilia A have been published in the medical journal…
Recently, the U.S. Food and Drug Administration (FDA) officially approved Carvykti (Ciltacabtagene Autoleucel, or Cilta-cel), a CAR-T cell therapy jointly developed by Johnson & Johnson and Legend Biotech, for the treatment of adult patients with…
Recently, the U.S. Food and Drug Administration (FDA) officially approved Turoctocog Alfa Pegol (brand name: Esperoct®), a new long-acting Factor VIII drug developed by Novo Nordisk, for the treatment of Hemophilia A. This groundbreaking drug…
On October 11, 2024, Junshi Biosciences announced that its self-developed recombinant humanized anti-PCSK9 monoclonal antibody injection, Ongericimab (brand name: JUNSHID®). Has been approved by the National Medical Products Administration (NMPA) for the treatment of adult…
In the rapidly advancing world of cancer treatment, Lunsumio(Mosunetuzumab) has emerged as a promising new therapy, offering hope to patients with certain types of B-cell non-Hodgkin lymphoma (NHL). This cutting-edge bispecific monoclonal antibody is poised…
Nimustine hydrochloride for Injection is used to treat gliomas and other brain tumors. As a nitrogen mustard drug, nimustine effectively inhibits tumor growth by interfering with DNA synthesis in cancer cells, helping patients prolong survival…
Fludarabine phosphate for injection is used to treat chronic lymphocytic leukemia (CLL) and non Hodgkin lymphoma (NHL). As an anti metabolic drug, it effectively inhibits the proliferation of cancer cells by suppressing their DNA synthesis,…
Retinoic acid (Tretinoin), a derivative of vitamin A, has long been widely used in dermatology, particularly in the treatment of acne and certain skin conditions. However, recent news and research on Tretinoin Tablets has been…
